M Lázaro Ríos

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Over the last 5 years, therapies for hepatitis C virus (HCV) infection have improved significantly, achieving sustained virologic response (SVR) rates of up to 100% in clinical trials in patients with HCV genotype 1. We investigated the effectiveness and safety of ombitasvir/paritaprevir/ritonavir±dasabuvir in an early access programme. This was a(More)
  • 1